This company listing is no longer active
VPA1 Stock Overview
AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VPA1 from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
AVEO Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.77 |
| 52 Week High | US$15.17 |
| 52 Week Low | US$2.80 |
| Beta | 0.98 |
| 1 Month Change | -1.36% |
| 3 Month Change | -7.83% |
| 1 Year Change | 358.69% |
| 3 Year Change | 155.00% |
| 5 Year Change | -43.57% |
| Change since IPO | -78.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| VPA1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.7% | -0.05% | -7.8% |
| 1Y | 358.7% | -18.7% | 1.8% |
Return vs Industry: VPA1 exceeded the German Biotechs industry which returned 10.7% over the past year.
Return vs Market: VPA1 exceeded the German Market which returned -12.9% over the past year.
Price Volatility
| VPA1 volatility | |
|---|---|
| VPA1 Average Weekly Movement | 1.9% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.9% |
Stable Share Price: VPA1's share price has been volatile over the past 3 months.
Volatility Over Time: VPA1's weekly volatility has decreased from 11% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 114 | Michael Bailey | www.aveooncology.com |
AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma.
AVEO Pharmaceuticals, Inc. Fundamentals Summary
| VPA1 fundamental statistics | |
|---|---|
| Market cap | €480.25m |
| Earnings (TTM) | -€26.74m |
| Revenue (TTM) | €86.87m |
5.5x
P/S Ratio-18.0x
P/E RatioIs VPA1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VPA1 income statement (TTM) | |
|---|---|
| Revenue | US$94.32m |
| Cost of Revenue | US$37.79m |
| Gross Profit | US$56.53m |
| Other Expenses | US$85.56m |
| Earnings | -US$29.04m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 59.93% |
| Net Profit Margin | -30.79% |
| Debt/Equity Ratio | 134.1% |
How did VPA1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/21 14:01 |
| End of Day Share Price | 2023/01/19 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AVEO Pharmaceuticals, Inc. is covered by 18 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| James Birchenough | BMO Capital Markets Equity Research |
| James Birchenough | BMO Capital Markets U.S. (Historical) |